Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
Identifieur interne : 000867 ( Istex/Corpus ); précédent : 000866; suivant : 000868Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
Auteurs : Robert A. Hauser ; Olivier Rascol ; Amos D. Korczyn ; A. Jon Stoessl ; Ray L. Watts ; Werner Poewe ; Peter P. De Deyn ; Anthony E. LangSource :
- Movement Disorders [ 0885-3185 ] ; 2007-12-15.
English descriptors
- KwdEn :
Abstract
In a 5‐year, double‐blind study, subjects with Parkinson's disease (PD) who were randomized to initial treatment with ropinirole had a significantly lower incidence of dyskinesia compared with subjects randomized to levodopa, although Unified Parkinson's Disease Rating Scale (UPDRS) motor scores were significantly more improved in the levodopa group. Subjects who completed the original study were eligible to participate in a long‐term extension study conducted according to an open, naturalistic design and were evaluated approximately every 6 months until they had been followed for a total of 10 years. Comparing subjects randomized to initial treatment with ropinirole (n = 42) and levodopa (n = 27), the incidence of dyskinesia was significantly lower in the ropinirole group (adjusted odds ratio [OR] = 0.3; 95% confidence interval [CI]: 0.1, 1.0; P = 0.046) and the median time to dyskinesia was significantly longer (adjusted hazard ratio = 0.4; 95% CI: 0.2, 0.8; P = 0.007). The incidence of at least moderate wearing off (“off” time ≥26% of the awake day) was also significantly lower in the ropinirole group (adjusted OR = 0.3; 95% CI: 0.09, 0.03; P = 0.03). There were no significant differences in change in UPDRS activities of daily living or motor scores, or scores for the 39‐item PD questionnaire, Clinical Global Impression, or the Epworth Sleepiness Scale. Early treatment decisions for individual patients depend largely on the anticipated risk of side effects and long‐term complications. Both ropinirole and levodopa are viable treatment options in early PD. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21743
Links to Exploration step
ISTEX:1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa</title><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation><mods:affiliation>University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, 4 Columbia Drive, Suite 410, Tampa, FL 33606</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>University Hospital, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name><affiliation><mods:affiliation>Tel Aviv University Medical School, Ramat Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Jon Stoessl, A" sort="Jon Stoessl, A" uniqKey="Jon Stoessl A" first="A." last="Jon Stoessl">A. Jon Stoessl</name><affiliation><mods:affiliation>University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation></author><author><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name><affiliation><mods:affiliation>University of Alabama, Birmingham, Alabama, USA</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>University of Innsbruck, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="De Deyn, Peter P" sort="De Deyn, Peter P" uniqKey="De Deyn P" first="Peter P." last="De Deyn">Peter P. De Deyn</name><affiliation><mods:affiliation>University of Antwerp, Antwerp, Belgium</mods:affiliation></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation><mods:affiliation>Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21743</idno><idno type="url">https://api-v5.istex.fr/document/1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000867</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000867</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa</title><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation><mods:affiliation>University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, 4 Columbia Drive, Suite 410, Tampa, FL 33606</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>University Hospital, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name><affiliation><mods:affiliation>Tel Aviv University Medical School, Ramat Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Jon Stoessl, A" sort="Jon Stoessl, A" uniqKey="Jon Stoessl A" first="A." last="Jon Stoessl">A. Jon Stoessl</name><affiliation><mods:affiliation>University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation></author><author><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name><affiliation><mods:affiliation>University of Alabama, Birmingham, Alabama, USA</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>University of Innsbruck, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="De Deyn, Peter P" sort="De Deyn, Peter P" uniqKey="De Deyn P" first="Peter P." last="De Deyn">Peter P. De Deyn</name><affiliation><mods:affiliation>University of Antwerp, Antwerp, Belgium</mods:affiliation></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation><mods:affiliation>Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-12-15">2007-12-15</date><biblScope unit="volume">22</biblScope><biblScope unit="issue">16</biblScope><biblScope unit="page" from="2409">2409</biblScope><biblScope unit="page" to="2417">2417</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1</idno><idno type="DOI">10.1002/mds.21743</idno><idno type="ArticleID">MDS21743</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>dopamine agonist</term><term>dyskinesia</term><term>levodopa</term><term>motor complications</term><term>ropinirole</term><term>treatment</term><term>wearing off</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In a 5‐year, double‐blind study, subjects with Parkinson's disease (PD) who were randomized to initial treatment with ropinirole had a significantly lower incidence of dyskinesia compared with subjects randomized to levodopa, although Unified Parkinson's Disease Rating Scale (UPDRS) motor scores were significantly more improved in the levodopa group. Subjects who completed the original study were eligible to participate in a long‐term extension study conducted according to an open, naturalistic design and were evaluated approximately every 6 months until they had been followed for a total of 10 years. Comparing subjects randomized to initial treatment with ropinirole (n = 42) and levodopa (n = 27), the incidence of dyskinesia was significantly lower in the ropinirole group (adjusted odds ratio [OR] = 0.3; 95% confidence interval [CI]: 0.1, 1.0; P = 0.046) and the median time to dyskinesia was significantly longer (adjusted hazard ratio = 0.4; 95% CI: 0.2, 0.8; P = 0.007). The incidence of at least moderate wearing off (“off” time ≥26% of the awake day) was also significantly lower in the ropinirole group (adjusted OR = 0.3; 95% CI: 0.09, 0.03; P = 0.03). There were no significant differences in change in UPDRS activities of daily living or motor scores, or scores for the 39‐item PD questionnaire, Clinical Global Impression, or the Epworth Sleepiness Scale. Early treatment decisions for individual patients depend largely on the anticipated risk of side effects and long‐term complications. Both ropinirole and levodopa are viable treatment options in early PD. © 2007 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Robert A. Hauser MD</name><affiliations><json:string>University of South Florida, Tampa, Florida, USA</json:string><json:string>Parkinson's Disease and Movement Disorders Center, University of South Florida, 4 Columbia Drive, Suite 410, Tampa, FL 33606</json:string></affiliations></json:item><json:item><name>Olivier Rascol MD, PhD</name><affiliations><json:string>University Hospital, Toulouse, France</json:string></affiliations></json:item><json:item><name>Amos D. Korczyn MD</name><affiliations><json:string>Tel Aviv University Medical School, Ramat Aviv, Israel</json:string></affiliations></json:item><json:item><name>A. Jon Stoessl MD</name><affiliations><json:string>University of British Columbia, Vancouver, British Columbia, Canada</json:string></affiliations></json:item><json:item><name>Ray L. Watts MD</name><affiliations><json:string>University of Alabama, Birmingham, Alabama, USA</json:string></affiliations></json:item><json:item><name>Werner Poewe MD</name><affiliations><json:string>University of Innsbruck, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Peter P. De Deyn MD</name><affiliations><json:string>University of Antwerp, Antwerp, Belgium</json:string></affiliations></json:item><json:item><name>Anthony E. Lang MD</name><affiliations><json:string>Toronto Western Hospital, Toronto, Ontario, Canada</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>treatment</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>ropinirole</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine agonist</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>levodopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dyskinesia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>wearing off</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>motor complications</value></json:item></subject><articleId><json:string>MDS21743</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>In a 5‐year, double‐blind study, subjects with Parkinson's disease (PD) who were randomized to initial treatment with ropinirole had a significantly lower incidence of dyskinesia compared with subjects randomized to levodopa, although Unified Parkinson's Disease Rating Scale (UPDRS) motor scores were significantly more improved in the levodopa group. Subjects who completed the original study were eligible to participate in a long‐term extension study conducted according to an open, naturalistic design and were evaluated approximately every 6 months until they had been followed for a total of 10 years. Comparing subjects randomized to initial treatment with ropinirole (n = 42) and levodopa (n = 27), the incidence of dyskinesia was significantly lower in the ropinirole group (adjusted odds ratio [OR] = 0.3; 95% confidence interval [CI]: 0.1, 1.0; P = 0.046) and the median time to dyskinesia was significantly longer (adjusted hazard ratio = 0.4; 95% CI: 0.2, 0.8; P = 0.007). The incidence of at least moderate wearing off (“off” time ≥26% of the awake day) was also significantly lower in the ropinirole group (adjusted OR = 0.3; 95% CI: 0.09, 0.03; P = 0.03). There were no significant differences in change in UPDRS activities of daily living or motor scores, or scores for the 39‐item PD questionnaire, Clinical Global Impression, or the Epworth Sleepiness Scale. Early treatment decisions for individual patients depend largely on the anticipated risk of side effects and long‐term complications. Both ropinirole and levodopa are viable treatment options in early PD. © 2007 Movement Disorder Society</abstract><qualityIndicators><score>8</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1616</abstractCharCount><pdfWordCount>5094</pdfWordCount><pdfCharCount>31910</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>250</abstractWordCount></qualityIndicators><title>Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa</title><genre><json:string>article</json:string></genre><host><title>Movement Disorders</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi><issn><json:string>0885-3185</json:string></issn><eissn><json:string>1531-8257</json:string></eissn><publisherId><json:string>MDS</json:string></publisherId><volume>22</volume><issue>16</issue><pages><first>2409</first><last>2417</last><total>9</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Research Article</value></json:item></subject></host><categories><wos><json:string>science</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string></inist></categories><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/mds.21743</json:string></doi><id>1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1</id><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api-v5.istex.fr/document/1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api-v5.istex.fr/document/1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api-v5.istex.fr/document/1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Copyright © 2007 Movement Disorder Society</p></availability><date>2007</date></publicationStmt><notesStmt><note>GlaxoSmithKline Research and Development</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa</title><author xml:id="author-1"><persName><forename type="first">Robert A.</forename><surname>Hauser</surname></persName><roleName type="degree">MD</roleName><affiliation>University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, 4 Columbia Drive, Suite 410, Tampa, FL 33606</affiliation></author><author xml:id="author-2"><persName><forename type="first">Olivier</forename><surname>Rascol</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>University Hospital, Toulouse, France</affiliation></author><author xml:id="author-3"><persName><forename type="first">Amos D.</forename><surname>Korczyn</surname></persName><roleName type="degree">MD</roleName><affiliation>Tel Aviv University Medical School, Ramat Aviv, Israel</affiliation></author><author xml:id="author-4"><persName><forename type="first">A.</forename><surname>Jon Stoessl</surname></persName><roleName type="degree">MD</roleName><affiliation>University of British Columbia, Vancouver, British Columbia, Canada</affiliation></author><author xml:id="author-5"><persName><forename type="first">Ray L.</forename><surname>Watts</surname></persName><roleName type="degree">MD</roleName><affiliation>University of Alabama, Birmingham, Alabama, USA</affiliation></author><author xml:id="author-6"><persName><forename type="first">Werner</forename><surname>Poewe</surname></persName><roleName type="degree">MD</roleName><affiliation>University of Innsbruck, Innsbruck, Austria</affiliation></author><author xml:id="author-7"><persName><forename type="first">Peter P.</forename><surname>De Deyn</surname></persName><roleName type="degree">MD</roleName><affiliation>University of Antwerp, Antwerp, Belgium</affiliation></author><author xml:id="author-8"><persName><forename type="first">Anthony E.</forename><surname>Lang</surname></persName><roleName type="degree">MD</roleName><affiliation>Toronto Western Hospital, Toronto, Ontario, Canada</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-12-15"></date><biblScope unit="volume">22</biblScope><biblScope unit="issue">16</biblScope><biblScope unit="page" from="2409">2409</biblScope><biblScope unit="page" to="2417">2417</biblScope></imprint></monogr><idno type="istex">1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1</idno><idno type="DOI">10.1002/mds.21743</idno><idno type="ArticleID">MDS21743</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>In a 5‐year, double‐blind study, subjects with Parkinson's disease (PD) who were randomized to initial treatment with ropinirole had a significantly lower incidence of dyskinesia compared with subjects randomized to levodopa, although Unified Parkinson's Disease Rating Scale (UPDRS) motor scores were significantly more improved in the levodopa group. Subjects who completed the original study were eligible to participate in a long‐term extension study conducted according to an open, naturalistic design and were evaluated approximately every 6 months until they had been followed for a total of 10 years. Comparing subjects randomized to initial treatment with ropinirole (n = 42) and levodopa (n = 27), the incidence of dyskinesia was significantly lower in the ropinirole group (adjusted odds ratio [OR] = 0.3; 95% confidence interval [CI]: 0.1, 1.0; P = 0.046) and the median time to dyskinesia was significantly longer (adjusted hazard ratio = 0.4; 95% CI: 0.2, 0.8; P = 0.007). The incidence of at least moderate wearing off (“off” time ≥26% of the awake day) was also significantly lower in the ropinirole group (adjusted OR = 0.3; 95% CI: 0.09, 0.03; P = 0.03). There were no significant differences in change in UPDRS activities of daily living or motor scores, or scores for the 39‐item PD questionnaire, Clinical Global Impression, or the Epworth Sleepiness Scale. Early treatment decisions for individual patients depend largely on the anticipated risk of side effects and long‐term complications. Both ropinirole and levodopa are viable treatment options in early PD. © 2007 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>Parkinson's disease</term></item><item><term>treatment</term></item><item><term>ropinirole</term></item><item><term>dopamine agonist</term></item><item><term>levodopa</term></item><item><term>dyskinesia</term></item><item><term>wearing off</term></item><item><term>motor complications</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-04-04">Received</change><change when="2007-08-21">Registration</change><change when="2007-12-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api-v5.istex.fr/document/1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="160"><doi origin="wiley" registered="yes">10.1002/mds.v22:16</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">16</numbering></numberingGroup><coverDate startDate="2007-12-15">15 December 2007</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="170" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21743</doi><idGroup><id type="unit" value="MDS21743"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2007 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2007-04-04"></event><event type="manuscriptRevised" date="2007-08-05"></event><event type="manuscriptAccepted" date="2007-08-21"></event><event type="firstOnline" date="2007-09-25"></event><event type="publishedOnlineFinalForm" date="2007-12-19"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2007-09-25"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2409</numbering><numbering type="pageLast">2417</numbering></numberingGroup><correspondenceTo>Parkinson's Disease and Movement Disorders Center, University of South Florida, 4 Columbia Drive, Suite 410, Tampa, FL 33606</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21743.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="4"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="24"></count><count type="wordTotal" number="5692"></count></countGroup><titleGroup><title type="main" xml:lang="en">Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa</title><title type="short" xml:lang="en">Ten‐Year Follow‐Up of Parkinson's Disease Patients</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Robert A.</givenNames><familyName>Hauser</familyName><degrees>MD</degrees></personName><contactDetails><email>rhauser@hsc.usf.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Olivier</givenNames><familyName>Rascol</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Amos D.</givenNames><familyName>Korczyn</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>A.</givenNames><familyName>Jon Stoessl</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Ray L.</givenNames><familyName>Watts</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Peter P.</givenNames><familyName>De Deyn</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af8"><personName><givenNames>Anthony E.</givenNames><familyName>Lang</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>University of South Florida, Tampa, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>University Hospital, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="IL" type="organization"><unparsedAffiliation>Tel Aviv University Medical School, Ramat Aviv, Israel</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="CA" type="organization"><unparsedAffiliation>University of British Columbia, Vancouver, British Columbia, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>University of Alabama, Birmingham, Alabama, USA</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="AT" type="organization"><unparsedAffiliation>University of Innsbruck, Innsbruck, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="BE" type="organization"><unparsedAffiliation>University of Antwerp, Antwerp, Belgium</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="CA" type="organization"><unparsedAffiliation>Toronto Western Hospital, Toronto, Ontario, Canada</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">treatment</keyword><keyword xml:id="kwd3">ropinirole</keyword><keyword xml:id="kwd4">dopamine agonist</keyword><keyword xml:id="kwd5">levodopa</keyword><keyword xml:id="kwd6">dyskinesia</keyword><keyword xml:id="kwd7">wearing off</keyword><keyword xml:id="kwd8">motor complications</keyword></keywordGroup><fundingInfo><fundingAgency>GlaxoSmithKline Research and Development</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>In a 5‐year, double‐blind study, subjects with Parkinson's disease (PD) who were randomized to initial treatment with ropinirole had a significantly lower incidence of dyskinesia compared with subjects randomized to levodopa, although Unified Parkinson's Disease Rating Scale (UPDRS) motor scores were significantly more improved in the levodopa group. Subjects who completed the original study were eligible to participate in a long‐term extension study conducted according to an open, naturalistic design and were evaluated approximately every 6 months until they had been followed for a total of 10 years. Comparing subjects randomized to initial treatment with ropinirole (n = 42) and levodopa (n = 27), the incidence of dyskinesia was significantly lower in the ropinirole group (adjusted odds ratio [OR] = 0.3; 95% confidence interval [CI]: 0.1, 1.0; <i>P</i> = 0.046) and the median time to dyskinesia was significantly longer (adjusted hazard ratio = 0.4; 95% CI: 0.2, 0.8; <i>P</i> = 0.007). The incidence of at least moderate wearing off (“off” time ≥26% of the awake day) was also significantly lower in the ropinirole group (adjusted OR = 0.3; 95% CI: 0.09, 0.03; <i>P</i> = 0.03). There were no significant differences in change in UPDRS activities of daily living or motor scores, or scores for the 39‐item PD questionnaire, Clinical Global Impression, or the Epworth Sleepiness Scale. Early treatment decisions for individual patients depend largely on the anticipated risk of side effects and long‐term complications. Both ropinirole and levodopa are viable treatment options in early PD. © 2007 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Ten‐Year Follow‐Up of Parkinson's Disease Patients</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa</title></titleInfo><name type="personal"><namePart type="given">Robert A.</namePart><namePart type="family">Hauser</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, 4 Columbia Drive, Suite 410, Tampa, FL 33606</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>University Hospital, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Amos D.</namePart><namePart type="family">Korczyn</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Tel Aviv University Medical School, Ramat Aviv, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Jon Stoessl</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>University of British Columbia, Vancouver, British Columbia, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ray L.</namePart><namePart type="family">Watts</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>University of Alabama, Birmingham, Alabama, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>University of Innsbruck, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Peter P.</namePart><namePart type="family">De Deyn</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>University of Antwerp, Antwerp, Belgium</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anthony E.</namePart><namePart type="family">Lang</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Toronto Western Hospital, Toronto, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-12-15</dateIssued><dateCaptured encoding="w3cdtf">2007-04-04</dateCaptured><dateValid encoding="w3cdtf">2007-08-21</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">4</extent><extent unit="tables">2</extent><extent unit="references">24</extent><extent unit="words">5692</extent></physicalDescription><abstract lang="en">In a 5‐year, double‐blind study, subjects with Parkinson's disease (PD) who were randomized to initial treatment with ropinirole had a significantly lower incidence of dyskinesia compared with subjects randomized to levodopa, although Unified Parkinson's Disease Rating Scale (UPDRS) motor scores were significantly more improved in the levodopa group. Subjects who completed the original study were eligible to participate in a long‐term extension study conducted according to an open, naturalistic design and were evaluated approximately every 6 months until they had been followed for a total of 10 years. Comparing subjects randomized to initial treatment with ropinirole (n = 42) and levodopa (n = 27), the incidence of dyskinesia was significantly lower in the ropinirole group (adjusted odds ratio [OR] = 0.3; 95% confidence interval [CI]: 0.1, 1.0; P = 0.046) and the median time to dyskinesia was significantly longer (adjusted hazard ratio = 0.4; 95% CI: 0.2, 0.8; P = 0.007). The incidence of at least moderate wearing off (“off” time ≥26% of the awake day) was also significantly lower in the ropinirole group (adjusted OR = 0.3; 95% CI: 0.09, 0.03; P = 0.03). There were no significant differences in change in UPDRS activities of daily living or motor scores, or scores for the 39‐item PD questionnaire, Clinical Global Impression, or the Epworth Sleepiness Scale. Early treatment decisions for individual patients depend largely on the anticipated risk of side effects and long‐term complications. Both ropinirole and levodopa are viable treatment options in early PD. © 2007 Movement Disorder Society</abstract><note type="funding">GlaxoSmithKline Research and Development</note><subject lang="en"><genre>keywords</genre><topic>Parkinson's disease</topic><topic>treatment</topic><topic>ropinirole</topic><topic>dopamine agonist</topic><topic>levodopa</topic><topic>dyskinesia</topic><topic>wearing off</topic><topic>motor complications</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>16</number></detail><extent unit="pages"><start>2409</start><end>2417</end><total>9</total></extent></part></relatedItem><identifier type="istex">1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1</identifier><identifier type="DOI">10.1002/mds.21743</identifier><identifier type="ArticleID">MDS21743</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000867 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000867 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1
|texte= Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
}}
| This area was generated with Dilib version V0.6.29. |  |